These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 1645988)

  • 1. Cisplatin-induced peripheral neurotoxicity: relationship to dose intensity.
    Pollera CF; Pietrangeli A; Giannarelli D
    Ann Oncol; 1991 Mar; 2(3):212. PubMed ID: 1645988
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-escalated paclitaxel in 1-hour infusion with a fixed dose of cisplatin in previously untreated advanced ovarian cancer: a phase II trial of the Spanish Group for Ovarian Cancer.
    Cervantes A; Mendiola C; del Campo JM; Massuti B; Casado A; Escobedo A; Moyano A; Ojeda B; Poveda A; Benito D
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-40-S15-43. PubMed ID: 9346221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral neurotoxicity following high-dose cisplatin with glutathione: clinical and neurophysiological assessment.
    Pirovano C; Balzarini A; Böhm S; Oriana S; Spatti GB; Zunino F
    Tumori; 1992 Aug; 78(4):253-7. PubMed ID: 1334604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy.
    Berger T; Malayeri R; Doppelbauer A; Krajnik G; Huber H; Auff E; Pirker R
    Eur J Cancer; 1997 Aug; 33(9):1393-9. PubMed ID: 9337680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity.
    Cavaletti G; Marzorati L; Bogliun G; Colombo N; Marzola M; Pittelli MR; Tredici G
    Cancer; 1992 Jan; 69(1):203-7. PubMed ID: 1309303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose (200 mg/m2) cisplatin-induced neurotoxicity in primary advanced ovarian cancer patients.
    Panici PB; Greggi S; Scambia G; Di Roberto P; Iacobelli S; Mancuso S
    Cancer Treat Rep; 1987 Jun; 71(6):669-70. PubMed ID: 3034424
    [No Abstract]   [Full Text] [Related]  

  • 7. A comparison of the incidence, duration, and degree of the neurologic toxicities of cisplatin-paclitaxel (PT) and cisplatin-cyclophosphamide (PC).
    Bacon M; James K; Zee B
    Int J Gynecol Cancer; 2003; 13(4):428-34. PubMed ID: 12911718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lhermitte's sign following oxaliplatin-containing chemotherapy in a cisplatin-pretreated ovarian cancer patient.
    Ciucci G; De Giorgi U; Leoni M; Bianchedi G
    Eur J Neurol; 2003 May; 10(3):328-9. PubMed ID: 12752412
    [No Abstract]   [Full Text] [Related]  

  • 9. High-dose cisplatin-related peripheral neuropathy.
    Ostchega Y; Donohue M; Fox N
    Cancer Nurs; 1988 Feb; 11(1):23-32. PubMed ID: 2834044
    [No Abstract]   [Full Text] [Related]  

  • 10. [Peripheral neuropathy produced by cisplatin].
    Valero Jiménez P; Murillo Capitán E; Sánchez Romero JA; Arbizu Ladrón de Guevara ML
    Rev Esp Oncol; 1984; 31(3):511-3. PubMed ID: 6085937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose intracavitary cisplatin with intravenous thiosulfate. Low incidence of serious neurotoxicity.
    Markman M; Cleary S; Pfeifle CE; Howell SB
    Cancer; 1985 Nov; 56(10):2364-8. PubMed ID: 2994877
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term neurotoxicity and Raynaud's phenomenon in patients treated with cisplatin-based chemotherapy for malignant ovarian germ cell tumor.
    Solheim O; Skalleberg J; Warncke T; Ørstavik K; Tropé C; Fosså SD
    Acta Obstet Gynecol Scand; 2019 Feb; 98(2):240-249. PubMed ID: 30289161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral neuropathy due to biweekly paclitaxel, epirubicin and cisplatin in patients with advanced ovarian cancer.
    Postma TJ; Hoekman K; van Riel JM; Heimans JJ; Vermorken JB
    J Neurooncol; 1999; 45(3):241-6. PubMed ID: 10845395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Limits to the "benefits" from our oncologic interventions: a case report.
    Markman M
    Gynecol Oncol; 2000 Aug; 78(2):261-2. PubMed ID: 10926815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose intensity combination chemotherapy for advanced epithelial ovarian carcinoma: results of a pilot study.
    Sweetenham JW; McKendrick JJ; Jones DH; Whitehouse JM; Williams CJ
    Br J Cancer; 1990 Feb; 61(2):319-22. PubMed ID: 2155645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cisplatin neurotoxicity.
    Cersosimo RJ
    Cancer Treat Rev; 1989 Dec; 16(4):195-211. PubMed ID: 2561592
    [No Abstract]   [Full Text] [Related]  

  • 17. High-dose, short-duration cisplatin/doxorubicin combination chemotherapy for advanced ovarian epithelial cancer.
    Hunter RE; Griffin TW; Stevens S; Roman LD; Bokhari F; Reale FR; Tak WK; Fitzgerald TJ; Dillon MB; Rose PG
    Cancer; 1991 Nov; 68(9):1890-4. PubMed ID: 1655227
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer.
    Soulié P; Bensmaïne A; Garrino C; Chollet P; Brain E; Fereres M; Jasmin C; Musset M; Misset JL; Cvitkovic E
    Eur J Cancer; 1997 Aug; 33(9):1400-6. PubMed ID: 9337681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study.
    Almadrones L; McGuire DB; Walczak JR; Florio CM; Tian C
    Oncol Nurs Forum; 2004 May; 31(3):615-23. PubMed ID: 15146227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.